Accuracy of PREDICT+ to Determine OS in Early Breast Cancer
Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer.
Elisa Agostinetto, MD of the Istituto Clinico Humanitas, Rozzano, Milan, Italy, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial (NCT00490139) of adjuvant lapatinib (Tykerb) with or without trastuzumab (Herceptin) versus trastuzumab alone in patients with HER2+ early breast cancer.
According to Agostinetto, PREDICT+ underestimated the survival of patients in the ALTTO trial. The 5-year overall survival (OS) prediction was 6.7 percentage points lower than what the actual 5-year OS was. These findings were consistent across all subgroups.
The greatest discrepancies were seen in patients with hormone receptor negative disease, node positive disease, and patients with larger tumor sizes. Discriminatory accuracy was also found to be low in the overall population. This finding was consistent across all subgroups.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
Study Reveals Encouraging Results in HER2+ Breast Cancer With Brain Mets
November 1st 2024Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.
Read More
